eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 10
 
Share:
Send email
Share:
Original paper

Assessment of serum Mac-2 binding protein glycosylation isomer as a potential marker for hepatocellular carcinoma in cirrhotic hepatitis C patients

Mohamed Gamal
1
,
Khaled Moheyeldin
1
,
Mona Wagdy
2
,
Nada Aposhady
1
,
Aly Elkady

  1. Department of Tropical Medicine, Faculty of Medicine, University of Alexandria, Egypt
  2. Department of Chemical and Clinical Pathology, Faculty of Medicine, University of Alexandria, Egypt
Clin Exp HEPATOL 2024; 10, 2: 90-97
DOI: https://doi.org/10.5114/ceh.2024.139981
Online publish date: 2024/06/18
Article file
- Assessment (8).pdf  [0.12 MB]
Get citation
 
PlumX metrics:
 
1. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017; 3: 1683-1691.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
5. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008; 395: 19-26.
6. Harimoto N, Itoh S, Yamanaka T, et al. Mac-2 binding protein glycosylation isomer as a prognostic marker for hepatocellular carcinoma with sustained virological response. Anticancer Res 2022; 42: 245-251.
7. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681.
8. Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS One 2015; 10: e0129053.
9. Yugawa K, Maeda T, Nagata S, et al. Mac-2-binding protein glycosylation isomer as a novel predictor of hepatocellular carcinoma recurrence in patients with hepatitis C virus eradication. Ann Surg Oncol 2022; 18: 2711-2719.
10. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563-1570.
11. Su TH, Peng CY, Tseng TC, et al. Serum mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B-related cirrhosis. J Infect Dis 2020; 221: 589-597.
12. Liu J, Hu HH, Lee MH, et al. Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients. Sci Rep 2017; 7: 14352.
13. Mak LY, To WP, Wong DKH, et al. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol 2019; 25: 1398.
14. Nagata H, Nakagawa M, Nishimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2- binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int 2016; 10: 956-964.
15. Zhao S, Wang M, Yang Z, et al. Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med 2020; 8: 539.
16. Tak KY, Jang B, Lee SK, et al. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol 2021; 36: 2917-2924.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.